the challenge of treatment resistance in patients with advanced egfr-mutated nsclc
Published 2 years ago • 160 plays • Length 1:26Download video MP4
Download video MP3
Similar videos
-
2:16
treatment resistance as a key challenge in patients with advanced nsclc
-
1:51
evaluating first-line therapies for egfr-mutated nsclc in 2024
-
3:27
paloma-3: subcutaneous vs intravenous amivantamab lazertinib in refractory egfr-mutated nsclc
-
31:53
perspectives on egfr-mutant and wildtype nsclc: tailoring treatment advances in late-stage disease
-
1:24
acquired resistance: facing the challenge of immunotherapy in patients with lung cancer
-
59:03
navigating rapid changes in first- and later-line treatment of egfr-mutated nsclc
-
12:21
泰格莎失敗後該怎麼辦?繼續標靶藥物?化學治療?免疫治療?
-
4:47
asco 2023 expert report on novelties in oncogene driven nsclc by a. curioni-fontecedro
-
2:28
amivantamab in patients with egfr ex20ins-mutated nsclc
-
1:10
dr besse on mechanisms of acquired resistance in egfr advanced nsclc
-
6:08
flaura study: a new standard of care for patients with egfr mutated nsclc
-
4:17
highlights on amivantamab after progression on osimertinib in egfr-mutated nsclc: mariposa-2
-
1:20
novel frontline approaches to treating patients with egfr-mutated nsclc
-
44:03
egfr: the challenge of primary and secondary resistance
-
58:24
time for even more precision in testing and treatment of egfr-mutated nsclc
-
2:21
osimertinib ipilimumab in egfr-mutated nsclc
-
1:41
physician perceptions of testing practices in patients with egfr mutated nsclc
-
1:05:12
new horizons in egfr-mutated nsclc: broadening the impact of precision testing
-
2:45
activity of egfr tkis in patients with nsclc with uncommon egfr mutations
-
4:02
treatment of egfr mutated nsclc - 2022 program: targeted therapies forum - english
-
1:09
current and novel treatment approaches for first-line egfr-m nsclc
-
3:34
repeat biopsy in lung cancer patients with egfr mutation